Literature DB >> 31889624

Oncologic impact of preoperative prognostic nutritional index change in resected pancreatic cancer following neoadjuvant chemotherapy.

Kang Hyun Kim1, Ho Kyoung Hwang2, In Cheon Kang2, Woo Jung Lee2, Chang Moo Kang3.   

Abstract

BACKGROUND: Although several studies have focused on the oncologic impact of the preoperative prognostic nutritional index (PNI), there is no study correlating the preoperative PNI changes with the oncologic outcome of resected pancreatic cancer following neoadjuvant chemotherapy (NAC).
METHODS: We retrospectively analyzed 107 pancreatic ductal adenocarcinoma patients who underwent NAC followed by surgical resection. ΔPNI was defined as post-NAC PNI subtracted from pre-NAC PNI. Patients were divided into high (≥-1.94, n = 54) and low ΔPNI groups (<-1.94, n = 53). Long-term oncologic outcomes, such as overall survival (OS) and disease-free survival (DFS), were compared. Univariate and multivariate analysis were used to identify independent prognostic factors.
RESULTS: The high ΔPNI group correlated with lower pre-NAC PNI (46.96 ± 4.68 vs. 51.77 ± 5.63, p < 0.001) and higher post-NAC PNI (50.05 ± 4.80 vs. 42.56 ± 7.44, p < 0.001) more than the low ΔPNI group. The high ΔPNI group was also associated with longer OS compared with the low ΔPNI group (mean OS: 63.97 months [95% CI: 49.95-77.99] vs. 41.16 months [95% CI: 27.66-54.66], p = 0.003); there was no significant difference in DFS (p > 0.05). Multivariate analysis revealed that low ΔPNI was an independent risk factor for OS (HR, 3.516; 95% CI, 1.885-6.558; p < 0.001), but not for DFS (p > 0.05).
CONCLUSIONS: Low ΔPNI (<-1.94) was an independent risk factor for the overall survival of resected pancreatic cancer patients following NAC. In the preoperative setting, improving the PNI can better the long-term oncologic outcome of this condition.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Neoadjuvant chemotherapy; Nutrition assessment; Pancreatic cancer; Prognostic nutritional index

Year:  2019        PMID: 31889624     DOI: 10.1016/j.pan.2019.12.006

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  4 in total

1.  Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma receiving liposomal irinotecan plus 5-fluorouracil and leucovorin.

Authors:  Yen-Yang Chen; Shun-Wen Hsueh; Shih-Hung Yang; Sz-Chi Chiu; Nai-Jung Chiang; Tai-Jan Chiu; Chung-Pin Li; Li-Yuan Bai; Chang-Fang Chiu; Shih-Chang Chuang; Yan-Shen Shan; De-Chuan Chan; Li-Tzong Chen; Chia-Jui Yen; Cheng-Ming Peng; Jen-Shi Chen; Wen-Chi Chou
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

2.  Prognostic value of prognostic nutritional index and its variations in advanced non-small-cell lung cancer patients treated with anlotinib monotherapy.

Authors:  Tian Chen; Gaofeng Liang; Zhenfei Xiang; Jinxian He; Xiaoyu Xu; Mengqiu Tang
Journal:  J Clin Lab Anal       Date:  2022-02-18       Impact factor: 2.352

3.  Geriatric nutritional risk index as a potential prognostic marker for patients with resectable pancreatic cancer: a single-center, retrospective cohort study.

Authors:  Naotake Funamizu; Akimasa Sakamoto; Takeshi Utsunomiya; Mio Uraoka; Tomoyuki Nagaoka; Miku Iwata; Chihiro Ito; Kei Tamura; Katsunori Sakamoto; Kohei Ogawa; Yasutsugu Takada
Journal:  Sci Rep       Date:  2022-08-11       Impact factor: 4.996

4.  A Nomogram Model Involving Preoperative Fibrinogen and Prognostic Nutritional Index Score for Predicting Postoperative Outcome in Patients with Gastric Cancer.

Authors:  Panxing Wang; Haijiang Wang; Guanglin Qiu; Jiahuang Liu; Lin Fan; Xinhua Liao; Xiangming Che
Journal:  Cancer Manag Res       Date:  2021-05-25       Impact factor: 3.989

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.